INTRODUCTION
Erectile dysfunction (ED) is defined as the inability to obtain or maintain an erection that is sufficient for a satisfactory sexual intercourse. This disease is very common and has two main origins: clinical (organic) and psychological. Vasculogenic, neurogenic and endocrine etiologies are among the most important organic causes of ED. 1 Vasculogenic ED may be caused by endothelial dysfunction 2 and shares several risk factors with cardiovascular diseases. 3, 4 Indeed, there is a body of evidence showing that not only cardiovascular factors increase ED risk 5 but ED seems to be an early marker for the future development of cardiovascular diseases. 3 On the other hand, neurogenic ED may be caused by diabetes-mediated impairment of non-adrenergic non-cholinergic neuronal fibers, 6 or be associated with physical trauma and nerve injury, which often occurs after radical prostatectomy. [7] [8] [9] In fact, 80% of patients who undergo this surgery present ED afterwards. 10 Phosphodiesterase-5 inhibitors, such as sildenafil or vardenafil, are the most used drugs to manage both vasculogenic and neurogenic ED. Although these treatments improved previous therapies, the clinical response to treatment is still below the expectations, with an average 70% rate of success. 11 Several factors may affect the responses to sildenafil, and it is possible that those factors modifying the nitric oxide (NO)-cyclic guanosine monophosphate pathway are the most relevant. Vascular endothelial growth factor (VEGF) is a cytokine involved in angiogenesis and it stimulates NO production, [12] [13] [14] [15] [16] [17] although NO may also stimulate VEGF production. [18] [19] [20] Particularly important for the diseased corpus cavernosum, VEGF exerts positive effects on endothelial, 12-15 neuronal 7, [21] [22] [23] [24] [25] and smooth muscle cells, thus improving erectile function (EF). 7, 14, 17, 21, 22, [26] [27] [28] [29] Moreover, sildenafil treatment improves VEGF signaling, 19, 30 and therefore VEGF may have a major role in the improved ED after chronic treatment with sildenafil, 31, 32 an effect that is maintained even after drug washout. 31 VEGF is encoded by a homonymous gene that has several functional polymorphisms. These polymorphisms may alter VEGF production 33, 34 and were associated with several cardiovascular diseases [35] [36] [37] [38] [39] [40] that may share pathogenic mechanisms with ED. In this study, we aimed at examining whether VEGF polymorphisms affect the responses to sildenafil in patients with clinical ED (CED) and in patients with postoperative ED (PED).
MATERIALS AND METHODS

Study population
The present work was carried out in accordance to the Helsinki declaration, and was approved by the Institutional Review Board at the Faculty of Medicine of Ribeirao Preto. We recruited 126 patients who were being followed up at the Urology Outpatient Clinic of the University Hospital of the Faculty of Medicine of Ribeirao Preto. Informed consent was obtained from all patients. They underwent a complete medical history and physical examination. Inclusion criteria were age between 40 and 80 years, complaints regarding sexual activity and medical diagnosis of ED. We excluded from our study all patients with endocrine or psychiatric disorders, neurogenic bladder dysfunction, hypogonadism, penile implants, cerebrovascular accident, central nervous system trauma and anatomical abnormalities such as Peyronie's disease. We excluded from the study those patients who did not use the prescribed doses of sildenafil at least eight times or who underwent prostatectomy within 1 year before the inclusion point. The exclusion criteria enriched our CED group with vasculogenic ED patients because we excluded other endocrine, neurogenic and anatomical causes for ED.
EF was evaluated before and after the use of sildenafil using the fiveitem version of the International Index for Erectile Function (5-IIEF) questionnaire, the EF domain. 41 Patients were divided into PED group (patients who underwent radical prostatectomy; n ¼ 66) and CED group (n ¼ 60). The response to sildenafil was evaluated after at least eight attempts of intercourse after sildenafil was used at 50 or 100 mg doses.
Sildenafil responsiveness was defined individually as the percentage of the maximum possible response (%MR) as follows: the 5-IIEF score before treatment was subtracted from the 5-IIEF score after treatment, and this difference was defined as DIIEF score. Then the 5-IIEF score before treatment was subtracted from 30 (maximum IIEF score) to calculate the maximum possible response (MPR). Finally, the DIIEF score was divided by MPR and multiplied by 100, thus giving a %MR. The patients were classified as good (GR) or poor (PR) responders if their %MR was above or below the median %MR, respectively. PED and CED patients were grouped as PR or GR independently of the etiology for ED, and comparison between PED and CED groups was avoided, unless to pinpoint differences between the groups.
Genotyping
Genomic DNA was extracted from 1 ml of venous blood samples by a salting-out method and stored at À 20 1C until analyzed. Three functional polymorphisms in the promoter region of VEGF were genotyped using Taqman Allele Discrimination Assays (Applied Biosystems, Foster City, CA, USA): -2578C4A (rs699947, assay ID C_8311602_10), -1154G4A (rs1570360, assay ID C_1647379_10) and -634G4C (rs2010963, assay ID C_8311614_10). PCRs were performed in a total volume of 10 ml (5 ng of template, 1X Taqman Genotyping Master Mix and 1X Taqman Allele Discrimination Assay). Thermal cycling was performed in standard conditions and fluorescence was recorded by the StepOne Plus Real-Time PCR equipment (Applied Biosystems). Results were analyzed with manufacturer's software.
Laboratory analyses
Serum lipid profile (total cholesterol, triglycerides, high-density lipoprotein cholesterol), glucose, testosterone, urea and creatinine concentrations were measured with commercially available kits using standardized techniques. Low-density lipoprotein concentration was calculated according to Friedewald's formula.
Haplotype inference and statistical analysis
Clinical features and biochemical parameters of the studied groups were compared by unpaired t-test (parametric data), by Mann-Whitney test (non-parametric data), or by w 2 -test (categorical variables). Allele, genotype and haplotype distributions were compared by w 2 -tests. Deviations from Hardy-Weinberg equilibrium were assessed by w 2 -test in whole sample without subdivisions, as all subjects were from the same population. Haplotypes were estimated using the program PHASE version 2.1 (http:// www.stat.washington.edu/stephens/software). The possible haplotypes including the three polymorphisms studied here in VEGF gene (-2578C4A, -1154G4A and -634G4C) were CGG, CGC, CAG, CAC, AGG, AGC, AAG and AAC. Haplotypes with frequencies o1% were not taken in consideration in the statistical analysis. A Po0.05 was considered as statistically significant in all analyses. However, the comparison of haplotype distributions required a Bonferroni's correction for multiple comparisons, and a Po0.0125 (0.05/number of observed haplotypes) was considered statistically significant.
RESULTS
The clinical features of the included subjects are shown in Table 1 . Although it was not the objective of our study to compare PED and CED groups, statistical analysis was performed to pinpoint differences between the studied groups. Patients in the PED group were older and had a higher frequency of diabetes mellitus than patients in the CED group (both Po0.05, Table 1 ). The other parameters were similar in the two groups (P40.05, Table 1 ). Table 2 shows the genotype and allele distributions in the CED and in the PED groups. We found no deviations from HardyWeinberg equilibrium for the three polymorphisms (all P40.05). We found no significant differences in genotype or allele distributions when the PED and the CED groups were compared (P40.05, Table 2 ). Table 3 shows the haplotype distributions in the PED and in the CED groups, which were not different (P ¼ 0.112, Table 3 ).
When we classified PED patients as PR and GR to sildenafil, we observed significant differences in genotype distributions for the -2578C4A and the -1154G4A polymorphisms (Po0.05, Table 4 ). The -1154AA genotype increased the risk of a worse response to sildenafil in PED patients (P ¼ 0.003; OR ¼ 19.93, 95% CI ¼ 1.13-350.0; Table 4 ), whereas the genotype -2578AA showed only a marginal association with poor response to sildenafil (P ¼ 0.072, Table 4 ).
In parallel with these results, we found that both -2578C4A and -1154G4A polymorphisms affected the responsiveness to sildenafil in the CED group (Po0.05; Table 5 ). We found an increased risk for worse responses to sildenafil in CED patients carrying the -2578CA (P ¼ 0.027; OR ¼ 2.01, 95% CI ¼ 1.08-3.74; Table 5 ), whereas we found a marginally significant association of -2578A allele with worse response to Sildenafil (P ¼ 0.082; Table 5 ). The haplotype analysis showed an overall difference in VEGF haplotype distributions in the CED group when PR and GR were compared (P ¼ 0.03; Table 6 ). Particularly, we found that the AAG haplotype was more common in PR than in GR patients (38% versus 20%, respectively, P ¼ 0.032; Table 6 ), thus increasing the risk for a worse response to sildenafil (OR ¼ 2.33, 95% CI ¼ 1.07-5.09). However, this finding does not resist to Bonferroni's correction for multiple comparisons (P40.0125). No significant differences were observed in haplotype distributions in the PED group when PR and GR were compared (P ¼ 0.899; Table 6 ).
Although the PR and GR in each PED and CED were paired by age, ethnicity, body mass index, and systolic and diastolic blood pressure, there were some differences in lipid fractions, fasting glucose and urea between PR and GR to sildenafil (Supplementary Table 1 ). All these parameters were within normal range, except for higher fasting glucose levels in GR patients with CED (Supplementary Table 1 ). In addition, we found an increased number of hypertensive subjects among PR in the CED group (Supplementary Table 1) .
DISCUSSION
This is the first study to examine whether functional VEGF polymorphisms are associated with variable responsiveness to sildenafil in patients with two distinct ED etiologies. The main findings of this study were that two polymorphisms in VEGF (-2578C4A and -1154G4A) affect the responsiveness of ED patients to sildenafil, regardless the etiology of ED. ED patients carrying the -1154AA genotype had an increased risk not responding very well to sildenafil treatment in both PED and CED groups. Although the association of the -2578AA with worse responses was significant only in the CED group, it Clinical ED (n ¼ 120)
Abbreviations: ED, erectile dysfunction; VEGF, vascular endothelial growth factor. Haplotype distributions were compared with highlight that there were no differences between postoperative and clinical groups. Frequencies are compared by w 2 tests. Po0.05 is considered statistically significant.
was near significance level in the PED group, and the overall genotypes distribution of -2578C4A was significantly different in PED patients when PR and GR were compared.
Moreover, we found significant differences in the overall haplotypes distribution in the CED group when PR and GR were compared. Abbreviations: CI, confidence interval; ED, erectile dysfunction; GR, good responders; PR, poor responders; VEGF, vascular endothelial growth factor. Genotype and allele distributions were compared by w 2 -test. Po0.05 is considered statistically significant. *Statistically significant. Table 6 . Distribution of haplotypes of VEGF polymorphisms in postoperative and clinical ED patients classified as PR and GR responders to sildenafil 
Abbreviations: CI, confidence interval; ED, erectile dysfunction; GR, good responders; OR, odds ratio; PR, poor responders; VEGF, vascular endothelial growth factor. Haplotype distributions were compared by w 2 -test. Haplotype CAG was excluded from statistical analysis due to its low frequency in whole sample (1 allele in 252 alleles studied here). For the general analysis, Po0.05 is considered statistically significant. For specific haplotype associations, we considered a P-value o0.0125 as statistically significant (Bonferroni's correction for multiple comparisons; 0.05/number of observed haplotypes). *Statistically significant.
The VEGF polymorphisms studied here have functional consequences. The AA genotype for the -2578C4A polymorphism reduces the expression of VEGF in mononuclear cells from peripheral blood, 34 whereas the -1154A allele apparently reduces the promoter activity by 25% when compared with the -1154G allele. 33 In addition, the -1154AA genotype was associated with reduced VEGF expression in mononuclear cells. 34 The C allele of the -634G4C polymorphism alters the two-dimensional structure of mRNA, thus leading to increased expression of one VEGF isoform (the L-VEGF). 33 Although the importance of this isoform for the human corpus cavernosum is not clear yet, 42 many previous studies support the idea that these VEGF polymorphisms may have clinical implications. [36] [37] [38] [39] 43, 44 Although the lack of response to sildenafil treatment is still poorly understood, it may involve genetic factors, especially those affecting the NO-cyclic guanosine monophosphate, 45 and this may include the VEGF signaling pathway.
The genetic associations we have found are consistent with the idea that the -2578A and -1154A alleles, which are associated with reduced VEGF expression, reduce VEGF signaling in the penis and this could be detrimental for EF and sildenafil response. Indeed, reduced VEGF expression and its receptors were shown in diabetic ED models, 46, 47 and this alteration was compensated by sildenafil treatment. 48 Moreover, increased soluble VEGFR-1 receptor has been shown in plasma from ED patients, and this is important because VEGFR-1 sequestrates VEGF and competes with the VEGFR-2 receptor, which is responsible for the main downstream VEGF signaling. 49 Moreover, VEGF injection improves EF in different ED models. 7, 14, 17, 21, 22, [26] [27] [28] [29] Finally, sildenafil treatment increases VEGF expression, 19, 30 and this effect could explain part of the long-term beneficial effects of chronic sildenafil treatment, 31, 32 which remain even after drug washout. 31 In addition to the significant genotype associations, we found a marginal association of the AAG haplotype with poor responses to sildenafil. This is consistent with previous results, indicating that this haplotype reduces hypoxia-induced VEGF expression by 35% when compared with wild-type haplotype. 33 This particular haplotype has also been found in association with amiothrophic lateral sclerosis, a disease that involves reduced VEGF signaling. 33 The notion that VEGF haplotypes may modulate NO production has been suggested in hypertension, 50 which is a clinical condition probably sharing common pathogenic mechanisms with vascular ED. 3, 4 Although the CAG haplotype reduced the risk for hypertension, it was also associated with increased levels of nitrates (a NO metabolite). 50 Unfortunately, the CAG haplotype is rare, and has not been found in our sample, and therefore we cannot examine whether this particular haplotype has any effects on the responsiveness to sildenafil.
Interestingly, the associations that we found are probably independent of the etiology for ED (either postoperativeneurogenic-or clinical). This may be explained by the fact that VEGF also activates different mechanisms that are impaired by CED or PED. For instance, VEGF improves endothelial and smooth muscle function by increasing endothelial NO synthase expression [12] [13] [14] [15] and activation, 16, 17 and by interfering with other mechanisms involved in vasculogenic ED. 2, 21, 47, 51 This is important because our CED group of patients was enriched with vascular ED explained by the exclusion of endocrine, neurogenic and other anatomical causes for ED. In addition, VEGF itself, 7, [21] [22] [23] [24] [25] or synergically with other cytokines, 28 promotes the recovery of damaged neurons. This is relevant as the first NO wave produced in the early stage of erection is released by afferent nonadrenergic non-cholinergic nerve fibers, 7 which are commonly damaged in patients who undergo prostatectomy. 7 Therefore VEGF may contribute to improve PED. Furthermore, given the close relationship between VEGF and NO, it is possible that lower VEGF levels could result in lower endothelial NO synthase activity, [12] [13] [14] [15] thus contributing to both PED and CED.
This study has some limitations. Although we studied a reasonable number of ED patients, we may have missed minor effects of VEGF polymorphisms or haplotypes. Although dividing ED patients into CED and PED groups reduces sample sizes, we believe that this approach is interesting because the phenotypes are more clearly defined, thus increasing the chances of finding more clear genetic associations with each etiology. We have also found slight differences in some biochemical parameters when GR and PR in PED and CED groups were compared. However, we believe that they may have minor effects, as biochemical parameters were within normal range, except for glucose levels.
Besides VEGF, there are other candidate genes that may have an impact on the responsiveness to sildenafil. We have previously shown that polymorphisms in the endothelial nitric oxide synthase (eNOS) gene affect the responses to sildenafil. 45 Other genes affecting the NO-cyclic guanosine monophosphate pathway may present polymorphisms that may modify the responses to sildenafil, and further studies should address this possibility, as well as epigenetic interactions between different genes. Finally, it would also be interesting to test the hypothesis that VEGF polymorphisms are associated with the risk of developing ED. However, this is clearly the subjects of another study.
In conclusion, VEGF polymorphisms affect the responsiveness of PED and CED patients to sildenafil. These results may help to improve the therapy of patients with ED.
